Introduction to health economics for the medical practitioner

Postgraduate Medical Journal

Volumn 79, Issue 929, 2003, Pages 147-150

  Kernick, D P ^a  

^a St Thomas' Medical Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENERAL PRACTITIONER; HEALTH CARE; HEALTH ECONOMICS; MEDICAL DECISION MAKING; MEDICAL PRACTICE; PRODUCTIVITY; REVIEW;

COST-BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS, MEDICAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; VALUE OF LIFE;

EID: 0037368511     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.929.147     Document Type: Review

References (11)

1. Drummond M. Economic analysis alongside control trials. London: Department of Health, March 1994.
2. Kernick D. Costing principles in primary care. Fam Pract 2000;17:1766-70.
3. Torgerson DJ, Spencer A. Marginal costs and benefits. BMJ 1996;312:35-6.
4. Pharoah P, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without existing coronary heart disease. BMJ 1996;312:1443-8.
5. Robinson R. Cost effective analysis. BMJ 1993;307:793-5.
6. Robinson R. Cost utility analysis. BMJ 1993;307:859-62.
7. Drummond M, Maynard A. Purchasing and providing cost effective health care. London: Churchill Livingstone, 1993.
8. Robinson R. Cost benefit analysis. BMJ 1993;307:924-6.
9. Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2001;18:557-66.
10. Mauskopf J, Paul J, Grant D, et al. The role of cost consequence analysis in health care decision making. Pharmacoeconomics 1998;13:277-88.
11. Pickin D, McCabe C, Ramsey L, et al. Cost effectiveness of statin treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32.